Orion
Anna Haapalinna is an experienced scientific and operational leader in research and development, currently serving as a Research Project Leader at Orion Corporation since April 2022, where responsibilities include managing biologics research phase projects in oncology. From October 2009 to July 2020, Anna held various roles at Orion Corporation, including leading small molecule research projects and coordinating medicinal chemistry activities. Anna's academic background includes a Ph.D. in Medicinal and Pharmaceutical Chemistry from the University of Eastern Finland and a Master of Science in Molecular Biotechnology and Diagnostics from the University of Turku, complemented by a Master of Science in Organic Chemistry from the University of Jyväskylä. Additional experience includes research positions at Aarhus University and the University of Eastern Finland, as well as teaching and project work in chemistry.
This person is not in the org chart
Orion
1 followers
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology, Finnish heritage rare diseases and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs.